Home - AME Clinical Trials Review

Join us at the IASLC 2026 World Conference on Lung Cancer

The IASLC 2026 World Conference on Lung Cancer (WCLC) is going to be held in Seoul, Republic of Korea from September 12th to 15th, 2026: https://wclc.iaslc.org/

This year AME Clinical Trials Review (ACTR), along with its sister journals and books published by AME Publishing Company, will be featured at this exciting academic event. We look forward to connecting with our authors, editorial board members, and readers on this exciting occasion. You are warmly invited to visit us at Booth 708. For your convenience, the official exhibition hall floor plan is available for reference.

We look forward to meeting you onsite!

A literature review and reflection on clinical trials: current challenges, future directions, and potential strategies to overcome practical barriers

Kaiping Zhang, Savvas Lampridis, Charles B. Simone II, Ionut Negoi, Yan Peng, Binghan Shang, Yao Lin, Yaling Cheng, Fanghui Yang, Vishal G. Shelat, Kamyar Kalantar-Zadeh
Review Article｜April 25, 2026
doi: 10.21037/actr-25-132

ACTR Annual Report 2025

Greetings from Dr. Kaiping Zhang and the Editorial Office of AME Clinical Trials Review (ACTR).

We are glad to present the 2025 Annual Report of ACTR, which has shown the author statistics, pageviews and visits of ACTR articles, as well as previews of upcoming reviews in the Education Channel and commentaries planned for the coming year.

AME and Wolters Kluwer aim to expand access to global medical research through new collaboration

The agreement broadens the reach of nearly 50 Open Access titles, contributing globally to over 5,000 articles

October 2, 2025 — Wolters Kluwer Health announced a new collaboration with AME Publishing Company, an Open Access publisher specializing in medical journals and books, headquartered in Hong Kong, China.

Reviewer of the Month (2026)

In 2026, ACTR reviewers continue to make outstanding contributions to the peer review process. They demonstrated professional effort and enthusiasm in their reviews and provided comments that genuinely help the authors to enhance their work.

Hereby, we would like to highlight some of our outstanding reviewers, with a brief interview of their thoughts and insights as a reviewer. Allow us to express our heartfelt gratitude for their tremendous effort and valuable contributions to the scientific process.

Interviews with Outstanding Authors (2025)

In 2025, many authors shared their insights on clinical trials in our journal. Their articles published with us have received very well feedback in the field and stimulate a lot of discussions and new insights among the peers.

Hereby, we would like to highlight some of our outstanding authors who have been making immense efforts in their research fields, with a brief interview of their unique perspectives and insightful views as authors.

The role of lisocabtagene maraleucel for relapsed/refractory follicular lymphoma: a commentary

Abigail T. Huetteman, Julio C. Chavez
Editorial Commentary｜February 25, 2026
doi: 10.21037/actr-25-18

Encorafenib, cetuximab and chemotherapy: a mole against BRAF mutant metastatic colorectal cancer

Benoist Chibaudel
Editorial Commentary｜February 25, 2026
doi: 10.21037/actr-25-80

From the PACIFIC to the ADRIATIC: a literature review of 38 years of failed maintenance trials in small cell lung cancer post-chemoradiation

Alexandria Lee, Misako Nagasaka, Sai-Hong Ignatius Ou, Zhaohui Liao Arter
Review Article｜February 25, 2026
doi: 10.21037/actr-25-71

First-line treatment strategies and potential prognostic factors in patients with KRAS G12C-mutant non-small cell lung cancer

Malak Alharbi, Nour Nassour, Vaishali Deenadayalan, Grace K. Dy
Review Article｜February 25, 2026
doi: 10.21037/actr-25-63

The role of minimal residual disease measurement in multiple myeloma

Bhavesh Mohan Lal, Nikhil Vojjala, Nikhila Sampath Kumar, Carolina Schinke
Review Article｜February 25, 2026
doi: 10.21037/actr-25-66

Clinical advancements in total neoadjuvant therapy for locally advanced rectal cancer: a narrative review

Angelo Pirozzi, Celine Hoyek, Naohiro Okano, Leticia Assad Maia Sandoval, Binbin Zheng-Lin, Oluseyi Abidoye, Cody Eslinger, Mohamad Bassam Sonbol, Mitesh J. Borad, Tanios S. Bekaii-Saab
Review Article｜February 25, 2026
doi: 10.21037/actr-25-58

‹ ›

Articles in Press

Past Issues

About actr

Manuscript Submission

AME Editing Service

Reprint & Permission

Advertising

Contact us

General editorial enquiries:
Email: actr@amegroups.com
Copyright related contact:
Email: permissions@amegroups.com
Commercial Sales contact (Reprints, advertising, etc.):
Email: sales@amegroups.com

Editorial Commentary

SURPASS-PEDS: clinical promise and priorities for future research on tirzepatide treatment for youth with type 2 diabetes

Wei Perng, Kristen Nadeau, Dana Dabelea

AME Clinical Trials Review

2026;

(25 August 2026)

PDF Full Text (74) Peer Review File COI Form Open Access

Editorial Commentary

Concurrent immune checkpoint blockade with chemoradiation: when more is less

Charles X. Wang, Sookyoung Joanna Kim, Megan E. Daly

AME Clinical Trials Review

2026;

(25 August 2026)

PDF Full Text (63) Peer Review File COI Form Open Access

Editorial Commentary

Lessons from PACIFIC-2 and the evolving landscape of unresectable stage III non-small cell lung cancer—when synergy blunts the benefit

Jairo Zuluaga, Juan Manuel Garzón-Dangond, Leonardo Rojas, Oscar Arrieta, Andrés F. Cardona

AME Clinical Trials Review

2026;

(25 August 2026)

PDF Full Text (68) Peer Review File COI Form Open Access

Editorial Commentary

Phacogoniotomy for advanced primary angle-closure glaucoma, from conceptual appeal to randomized evidence

Anand Kumar Pathak, Viney Gupta, Shikha Gupta

AME Clinical Trials Review

2026;

(25 August 2026)

PDF Full Text (55) Peer Review File COI Form Open Access

Editorial Commentary

Sunvozertinib redraws the map in EGFR ex20ins mutant non-small cell lung cancer

Huawei Chen, Hongmei Jiang, Qing Wu, Yu Xu

AME Clinical Trials Review

2026;

(25 August 2026)

PDF Full Text (56) Peer Review File COI Form Open Access

Editorial Commentary

Ribociclib in early breast cancer: interpreting the 4-year outcomes of the NATALEE trial

Prajakta P. Masurkar, Swarnali Goswami

AME Clinical Trials Review

2026;

(25 August 2026)

PDF Full Text (67) Peer Review File COI Form Open Access

Editorial Commentary

Balloon-based percutaneous coronary intervention in multilayer in-stent restenosis

Gianmaria Calamita, Pier Pasquale Leone, Azeem Latib

AME Clinical Trials Review

2026;

(25 August 2026)

PDF Full Text (57) Peer Review File COI Form Open Access

Editorial Commentary

Interpreting JCOG1409 (MONET): what does non-inferiority really mean for minimally invasive oesophagectomy?

Michael Patrick Achiam, Pieter de Heer

AME Clinical Trials Review

2026;

(25 August 2026)

PDF Full Text (48) Peer Review File COI Form Open Access

Editorial Commentary

HARMONi-6 trial: a further development in the management of advanced squamous non-small-cell lung cancer

Alessia Angela Guarino, Alfonso Fiorelli

AME Clinical Trials Review

2026;

(25 August 2026)

PDF Full Text (43) Peer Review File COI Form Open Access

Editorial Commentary

Direction of guidelines about drug-coated balloon angioplasty for in-stent restenosis of drug-eluting stents

Taro Takeyama, Tetsuya Ishikawa, Yoshihiro Mera, Miona Arai, Isao Taguchi

AME Clinical Trials Review

2026;

(25 August 2026)

PDF Full Text (49) Peer Review File COI Form Open Access

Editorial Commentary

Timing, technique and the challenges in non-culprit vessel revascularisation: a critical look at the iMODERN Trial

Aatish Rengan, Atit A. Gawalkar

AME Clinical Trials Review

2026;

(25 August 2026)

PDF Full Text (66) Peer Review File COI Form Open Access

Review Article

Rituximab combinations in hairy cell leukemia

Tadeusz Robak

AME Clinical Trials Review

2026;

(25 August 2026)

PDF Full Text (54) Peer Review File COI Form Open Access

Editorial Commentary

The dry retina paradox: interpreting MERLIN in clinical practice

Lasse J. Cehofski, Yousif Subhi

AME Clinical Trials Review

2026;

(25 June 2026)

PDF Full Text (196) Peer Review File COI Form Open Access

Editorial Commentary

Ivonescimab, a PD-1/VEGF bispecific antibody, challenges pembrolizumab monotherapy in PD-L1-positive non-small cell lung cancer: insights from HARMONi-2

Mariem Galuia, Mark A. Socinski

AME Clinical Trials Review

2026;

(25 June 2026)

PDF Full Text (1592) Peer Review File COI Form Open Access

Editorial Commentary

Androgen deprivation therapy and definitive radiotherapy for intact prostate cancer in the modern era: personalized medicine on the horizon

Joshua R. Niska, Nathan Y. Yu, Jean-Claude M. Rwigema, Sarah E. James, Brady S. Laughlin, Carlos E. Vargas, Steven E. Schild

AME Clinical Trials Review

2026;

(25 June 2026)

PDF Full Text (233) Peer Review File COI Form Open Access

Editorial Commentary

We will not have to wait—building regulatory confidence in early endpoints for high-risk breast cancer

Keli Santos-Parker, Laura Esserman

AME Clinical Trials Review

2026;

(25 June 2026)

PDF Full Text (189) Peer Review File COI Form Open Access

Editorial Commentary

Precision in practice: a new standard in early-relapsing HR+ breast cancer

Nathalie LeVasseur, Karen A. Gelmon

AME Clinical Trials Review

2026;

(25 June 2026)

PDF Full Text (271) Peer Review File COI Form Open Access

Editorial Commentary

Less is more: lessons from adding antiangiogenesis to 1L chemo-immunotherapy in non-small cell lung cancer (LEAP-006)

Federico Monaca, Igor Gómez-Randulfe, Raffaele Califano

AME Clinical Trials Review

2026;

(25 June 2026)

PDF Full Text (189) Peer Review File COI Form Open Access

Editorial Commentary

EPIK-O and beyond: PI3Kα inhibition plus PARP blockade in platinum-resistant BRCA-wildtype ovarian cancer

Mali Barbi, Divya Bhana, Veena S. John

AME Clinical Trials Review

2026;

(25 June 2026)

PDF Full Text (212) Peer Review File COI Form Open Access

Editorial Commentary

Neoadjuvant osimertinib: a new standard in resectable EGFR-mutated non-small cell lung cancer?

Takahiro Karasaki

AME Clinical Trials Review

2026;

(25 June 2026)

PDF Full Text (1025) Peer Review File COI Form Open Access

View more articles

Currently no content available!

Editorial Commentary

KEYNOTE-189 5-years update: setting a backbone for the next generation clinical research in advanced non-squamous non-small cell lung cancer without oncogenic addiction

Alessandra Merlini, Anis Cipi, Giorgia Ferrari, Paolo Bironzo

Published online: 11 June 2024

PDF Full Text (21594) Peer Review File COI Form Open Access

Editorial Commentary

Xaluritamig: a first step towards a new target, new mechanism for metastatic prostate cancer

Ruben Raychaudhuri, Michael T. Schweizer, Jessica E. Hawley, Lawrence Fong, Evan Y. Yu

Published online: 15 August 2024

PDF Full Text (18163) Peer Review File COI Form Open Access

Review Article

First-line treatment strategies and potential prognostic factors in patients with KRAS G12C-mutant non-small cell lung cancer

Malak Alharbi, Nour Nassour, Vaishali Deenadayalan, Grace K. Dy

Published online: 26 September 2025

PDF Full Text (16043) Peer Review File COI Form Open Access

Editorial Commentary

Assessing the UNICANCER-PRODIGE 23 trial through the lens of nonoperative management

Wini Zambare, Aron Bercz, J. Joshua Smith

Published online: 13 May 2025

PDF Full Text (14130) Peer Review File COI Form Open Access

Editorial Commentary

Yes to adjuvant osimertinib therapy in EGFR-mutated stage IB–IIIA non-small cell lung cancer post resection, but for how long? (ADAURA/NCT02511106)

Faustine Luo, Sai-Hong Ignatius Ou, Misako Nagasaka

Published online: 21 June 2024

PDF Full Text (13842) Peer Review File COI Form Open Access

Editorial Commentary

The Butterfly effect—will the MARIPOSA-2 study alter the trajectory of EGFR mutated non-small cell lung cancer (NSCLC)

Yuji Uehara, Aaron C. Tan

Published online: 06 June 2024

PDF Full Text (13347) Peer Review File COI Form Open Access

Editorial Commentary

Neoadjuvant FOLFIRINOX in resectable pancreatic cancer: impact of the NORPACT-1 trial

Eva Versteijne, Geertjan van Tienhoven, Anna M. E. Bruynzeel, Johanna W. Wilmink, Marc G. Besselink, Bas Groot Koerkamp; on behalf of the Dutch Pancreatic Cancer Group

Published online: 20 December 2024

PDF Full Text (12090) Peer Review File COI Form Open Access

Editorial Commentary

FLAURA in the real world: osimertinib in potentially trial-eligible and ineligible patients with EGFR-mutated advanced non-small cell lung cancer

Faustine X. Luo, Zhaohui Liao Arter, Sai-Hong Ignatius Ou, Misako Nagasaka

Published online: 04 December 2024

PDF Full Text (11966) Peer Review File COI Form Open Access

Editorial Commentary

Intracranial efficacy of adagrasib in patients with KRAS G12C mutated non-small cell lung cancer (NSCLC): are results KRYSTAL clear?

Anuja Abhyankar, Grace K. Dy

Published online: 21 August 2024

PDF Full Text (11664) Peer Review File COI Form Open Access

Editorial Commentary

Eradication of Helicobacter pylori and its impact on the incidence of gastric cancer

Luis Guilherme de Oliveira Silva, Fabian Fellipe Bueno Lemos, Fabrício Freire de Melo

Published online: 08 May 2025

PDF Full Text (10759) Peer Review File COI Form Open Access

Review Article

Clinical advancements in total neoadjuvant therapy for locally advanced rectal cancer: a narrative review

Angelo Pirozzi, Celine Hoyek, Naohiro Okano, Leticia Assad Maia Sandoval, Binbin Zheng-Lin, Oluseyi Abidoye, Cody Eslinger, Mohamad Bassam Sonbol, Mitesh J. Borad, Tanios S. Bekaii-Saab

Published online: 26 September 2025

PDF Full Text (10587) Reporting Checklist Peer Review File COI Form Open Access

Editorial Commentary

The optimum balance between efficacy and toxicity with different doses of trastuzumab deruxtecan in HER2 mutated non-small cell lung cancer in DESTINY-Lung02 trial

Saurav Verma, Jacques Raphael

Published online: 02 September 2024

PDF Full Text (10284) Peer Review File COI Form Open Access

Editorial Commentary

Immunotherapy as the new standard of care for advanced endometrial cancer

Giovanna Vieira Giannecchini, Martina Parenza Arenhardt, Andreia Cristina de Melo

Published online: 03 April 2025

PDF Full Text (9989) Peer Review File COI Form Open Access

Editorial Commentary

Post-CDK4/6i wars in HR⁺/HER2⁻ breast cancer: is elacestrant a solid contender through the lens of precision oncology

Ünal Metin Tokat, Nalan Babacan, Mutlu Demiray

Published online: 01 July 2025

PDF Full Text (9641) Peer Review File COI Form Open Access

Editorial Commentary

Is zilebesiran a novel effective and uniquely administered agent for an expanding therapeutic armamentarium for blood pressure control?

John M. Flack

Published online: 24 February 2025

PDF Full Text (9214) Peer Review File COI Form Open Access

Editorial Commentary

Unpacking prostate-specific antigen dynamics and patient outcomes: insights from the ARASENS trial

Hayley Nicole Roberts, Corinne Maurice-Dror, Kim Nguyen Chi

Published online: 21 February 2025

PDF Full Text (9009) Peer Review File COI Form Open Access

Review Article

Recent updates in targeted therapy for advanced non-small cell lung cancer with actionable genomic alterations: a narrative review

Fangdi Sun, Joel W. Neal

Published online: 21 July 2025

PDF Full Text (8657) Reporting Checklist Peer Review File COI Form Open Access

Editorial Commentary

Optimizing antiplatelet therapy after coronary artery bypass graft: selection, dosing, and duration

Lokeswara Rao Sajja, Pradeep Narayan, Sanjeeth Peter

Published online: 17 December 2024

PDF Full Text (8627) Peer Review File COI Form Open Access

Editorial Commentary

Induction therapy for acute myeloid leukemia: still nothing beyond 7+3?

Daniela Damiani, Mario Tiribelli

Published online: 20 June 2024

PDF Full Text (8563) Peer Review File COI Form Open Access

Review Article

The role of minimal residual disease measurement in multiple myeloma

Bhavesh Mohan Lal, Nikhil Vojjala, Nikhila Sampath Kumar, Carolina Schinke

Published online: 26 September 2025

PDF Full Text (8558) Peer Review File COI Form Open Access

Full Most Read article list >>

Journal Highlight more

AME Clinical Trials Review (AME Clin Trials Rev; ACTR) is an international, open-access, peer-reviewed online journal, publishing commentaries on all phases of clinical trials, including but not limited to the design, conduct, analysis, regulation and ethics. It is dedicated to sharing insights of the key opinion leaders to stimulate thought and discussion in clinical trials and facilitate the translation of the findings of clinical trials from bench to bedside, and to clinical practice. More >>

Clinical Trials Education Channel

The Clinical Trials Education Channel aims to publish Review Article of high educational value that can guide the better understanding and practice of the whole cycle of clinical trials, including ethics, methodological design, analysis, reporting, appraisal, and supervision. More >>